JP2009526868A - 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 - Google Patents

新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 Download PDF

Info

Publication number
JP2009526868A
JP2009526868A JP2008555484A JP2008555484A JP2009526868A JP 2009526868 A JP2009526868 A JP 2009526868A JP 2008555484 A JP2008555484 A JP 2008555484A JP 2008555484 A JP2008555484 A JP 2008555484A JP 2009526868 A JP2009526868 A JP 2009526868A
Authority
JP
Japan
Prior art keywords
alkyl
alkylenyl
group
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008555484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526868A5 (https=
Inventor
クー，ユイ・コイ
シウ，シアンドン
ウエイツバーグ，モシエ
シヤム，ヒン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2009526868A publication Critical patent/JP2009526868A/ja
Publication of JP2009526868A5 publication Critical patent/JP2009526868A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008555484A 2006-02-15 2007-02-15 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 Ceased JP2009526868A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77351406P 2006-02-15 2006-02-15
PCT/US2007/062181 WO2007095603A2 (en) 2006-02-15 2007-02-15 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome

Publications (2)

Publication Number Publication Date
JP2009526868A true JP2009526868A (ja) 2009-07-23
JP2009526868A5 JP2009526868A5 (https=) 2013-01-24

Family

ID=38330470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555484A Ceased JP2009526868A (ja) 2006-02-15 2007-02-15 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用

Country Status (6)

Country Link
US (1) US8735595B2 (https=)
EP (1) EP1991536A2 (https=)
JP (1) JP2009526868A (https=)
CN (1) CN101384568B (https=)
CA (1) CA2641766A1 (https=)
WO (1) WO2007095603A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016084816A1 (ja) * 2014-11-26 2016-06-02 武田薬品工業株式会社 二環性化合物
JP2016520063A (ja) * 2013-05-10 2016-07-11 ニンバス アポロ，インコーポレーテッド Ａｃｃ阻害剤及びその使用
JPWO2016159049A1 (ja) * 2015-03-31 2018-03-01 武田薬品工業株式会社 単環式化合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
CN101484433A (zh) * 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
MX2009012613A (es) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
EP2947082A1 (en) 2009-11-10 2015-11-25 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
AU2012245996B2 (en) 2011-04-22 2016-09-01 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
JP6417401B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
DK3013813T3 (da) 2013-06-27 2019-06-03 Pfizer Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
US20160220557A1 (en) 2013-09-12 2016-08-04 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171848A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
JP2000505052A (ja) * 1996-01-05 2000-04-25 ノバルティス アクチェンゲゼルシャフト 除草剤として役立つ置換化１，２，４，６―チアトリアジン
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
WO2005012262A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005021529A1 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
JP2005272476A (ja) * 2003-04-09 2005-10-06 Japan Tobacco Inc 複素芳香５員環化合物及びその医薬用途
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
JP2008527043A (ja) * 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196876A (ja) 1983-04-22 1984-11-08 Sumitomo Chem Co Ltd １，２，４−オキサジアゾ−ル誘導体、その製造法およびそれを有効成分とする除草剤
WO1986003203A1 (fr) * 1984-11-22 1986-06-05 Yoshitomi Pharmaceutical Industries, Ltd. Derives de thienylthiazole
CA2044533A1 (en) * 1990-06-29 1991-12-30 Philippe Guerry Substituted aminoalkylbiphenyl derivatives
WO1995032963A1 (en) * 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
AU3087195A (en) 1994-08-02 1996-03-04 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
WO1996006096A1 (en) * 1994-08-23 1996-02-29 Nissan Chemical Industries, Ltd. Pyridine derivative
DE19536809A1 (de) 1995-10-02 1997-04-03 Basf Ag Heterocyclisch substituierte Salicylsäurederivate
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
US6268308B1 (en) 1996-08-27 2001-07-31 Syngenta Crop Protection, Inc. Herbicidal S-substituted 1,2,4,6-thiatriazines
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1356276A4 (en) 2000-12-26 2005-02-02 Res Dev Foundation ACETYL-COENZYME A CARBOXYLASE 2 AS A TARGET IN THE REGULATION OF BULK FAT, FAT STORAGE, ENERGY HOMEOSTASY AND INSULIN ACTION
HRP20031002A2 (en) 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
AU2002324045C1 (en) * 2001-08-13 2008-05-29 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
CN1642599A (zh) * 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
EP1572629A1 (en) * 2002-12-12 2005-09-14 Galderma Research & Development, S.N.C. COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
WO2004089918A1 (ja) * 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
MXPA05012679A (es) 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
JP4638423B2 (ja) 2003-06-20 2011-02-23 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用
GB2404855A (en) 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1677791A4 (en) 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
WO2005051945A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006022065A (ja) 2004-07-09 2006-01-26 Dai Ichi Seiyaku Co Ltd カルバメート誘導体
CN101031555A (zh) * 2004-07-27 2007-09-05 安斯泰来制药有限公司 具有vap－1抑制活性的噻唑衍生物
CN101484433A (zh) * 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2008079610A2 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EP2581081A3 (en) * 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505052A (ja) * 1996-01-05 2000-04-25 ノバルティス アクチェンゲゼルシャフト 除草剤として役立つ置換化１，２，４，６―チアトリアジン
JPH11171848A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005272476A (ja) * 2003-04-09 2005-10-06 Japan Tobacco Inc 複素芳香５員環化合物及びその医薬用途
WO2005012262A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005021529A1 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
JP2008527043A (ja) * 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520063A (ja) * 2013-05-10 2016-07-11 ニンバス アポロ，インコーポレーテッド Ａｃｃ阻害剤及びその使用
WO2016084816A1 (ja) * 2014-11-26 2016-06-02 武田薬品工業株式会社 二環性化合物
JPWO2016159049A1 (ja) * 2015-03-31 2018-03-01 武田薬品工業株式会社 単環式化合物

Also Published As

Publication number Publication date
WO2007095603A3 (en) 2008-03-13
EP1991536A2 (en) 2008-11-19
CN101384568B (zh) 2012-12-12
CN101384568A (zh) 2009-03-11
WO2007095603A2 (en) 2007-08-23
US8735595B2 (en) 2014-05-27
CA2641766A1 (en) 2007-08-23
US20070219251A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
JP2009526868A (ja) 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
JP5291471B2 (ja) 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
JP5369257B2 (ja) 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
US7928243B2 (en) Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US6706743B2 (en) β3 adrenergic receptor agonists and uses thereof
HRP20040810A2 (en) Thiazole and oxazole derivatives that modulate ppar activity
US7998993B2 (en) TRPV1 antagonists
ES2220504T3 (es) Derivados del aminotiazol y su uso como ligandos receptores de crf.
JP5410969B2 (ja) ２，４，５−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用
US20060178400A1 (en) Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
CN107739378A (zh) 吲哚嗪衍生物及其在医药上的应用
US20050075323A1 (en) Beta3 adrenergic receptor agonists and uses thereof
CN102388025A (zh) 用作p38mapk抑制剂的嘧啶并哒嗪衍生物
MX2008010469A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2008010467A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2008010471A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120828

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20121101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121127

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121212

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131112

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131210

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140422